Healios K.K. (OTCMKTS:HLOSF – Get Free Report) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 148,399 shares, a decrease of 57.3% from the December 31st total of 347,749 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.
Healios K.K. Price Performance
OTCMKTS:HLOSF remained flat at $2.10 during trading hours on Thursday. The company’s fifty day simple moving average is $2.38 and its 200 day simple moving average is $3.31. Healios K.K. has a 1-year low of $1.90 and a 1-year high of $4.45.
About Healios K.K.
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
See Also
- Five stocks we like better than Healios K.K.
- Do not delete, read immediately
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
